Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (April 2023)

37 slides from Windtree Therapeutics's investor presentation, Apr 3, 2023

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics \ Company Overview April 3, 2023 Se we WINDTREE (NASDAQ: WINT)

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements ‘This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's

  3. Slide 3: Windtree Therapeutics and Istaroxime Highlights

    Windtree Therapeutics and Istaroxime Highlights v qq Biopharmaceutical company with advanced clinical focus on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has consi

  4. Slide 4: Pipeline

    Pipeline Lead Products |indicaton Istaroxime ‘Cardiogenic Shock Istaroxime ‘Acute Heart Failure OralSERCA2a Chronic Heart Failure, including Activators potentially HFPEF Treatment Resistant Rostafuroxin Hypertension - Genetically ‘Assocated KLASurfactant KU4 sufactat DrugDevce Tx Ce RERa Ga for RDS

  5. Slide 5: Istaroxime: Cardiogenic Shock

    Istaroxime Cardiogenic Shock Potential indication in active clinical development

  6. Slide 6: Cardiogenic Shock

    Cardiogenic Shock A severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high filling pressures of the heart and decreased urine output. Itis a treatment emergency. » Caused by severe impairment of cardiac function that results in diminished

  7. Slide 7: Market Research: Early Cardiogenic Shock Treatment

    Market Researc! Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need * No satisfactory pharmacological intervention to reverse the conditions ~ Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, rena

  8. Slide 8: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action Stimulation of SERCA2a activity Inhibition of the soaium- . @ crimes acum reuptae potassium pump and effects on Istaroxime Teaulti

  9. Slide 9: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials

    Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials Phase 2a and 2b data in AHF demonstrated istaroxime uniquely and significantly improved: vw Cardiac Function + increased stroke volume lowered cardiac filling pressures vo Dose Related Increases in Systolic Blood Pressure iv

  10. Slide 10: Cardiogenic Shock Treatment: Regulatory Pathway

    Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Regulatory Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Oo | ‘Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drug

  11. Slide 11: SEISMiC Early Cardiogenic Shock Study

    SEISMIC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure Ze 60 patients in early cardiogenic shock (SBP 75-0mmHg) with AHF + Study drug was infused for 24 hours ina 1:1 randomization to placebo or istaroxime. T

  12. Slide 12: Primary Endpoint: Difference in SBP Profile

    eta Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population 3" stanne zn lacebo EL Change from Baseline in SBP 0 os 1 is 2 28 3 40455 35) 6 8g Hours from Infusion Inititation WINDTREE

  13. Slide 13: Secondary Results: Systolic BP Improvements Persisted over 24 Hours

    & Secondary Results — Systolic BP Improvements Persisted over 24 Hours ‘Systolic Blood Pressure mITT Population € 2 Istaroxime © Placebo Change in SBP (mmHg) } t { p=0.025 for AUC 0 2 24 Hours from Infusion initiation

  14. Slide 14: Cardiac Function Improvement

    Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: * Cardiac index significantly increased » Stroke volume index substantially increased (4 mL/m2) approaching statistical significance » Other echocardiographic me

  15. Slide 15: Treatment was Associated with a Favorable Renal Profile

    Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients , —____________ Estimated Glomerular Filtration Rate ‘miTT Population eo Istaroxime ‘change trom Baseline in GFR (miminit.73m°) 5) =e Pracedo 2 ° 2 as 36 * cy 2 ee 8 ours from infu

  16. Slide 16: Comparison of Doses

    & Comparison of Doses 1.0 yg/kg/min Produced a Favorable Effect on SBP 1.0 ugikg/min dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function * More favorable adverse event, serious adverse event and clinical event profile 210

  17. Slide 17: SEISMiC Results Summary

    SEISMiC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) » SBP increases were rapi

  18. Slide 18: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy se fd WINDTREE SEISMIC Extension Study = Extended and titrated dosing for optimization SEISMIC * Additional characterization Phase 3* Sf SENEA a eet + Execute EOP2 meeting Study with these 3 studies augmented by AHF * Proof of Concept SS) safety data base, etc.

  19. Slide 19: Plan for Dose Optimization — Extension Study

    Plan for Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ‘ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associ

  20. Slide 20: Cardiogenic Shock Opportunity

    Cardiogenic Shock Opportunity ITENDED TARGET THERAPEUTIC PROFILE For patients in cardiogenicshock due to heart failure, istaroxime will be a unique, first-in-class dual action agent anda treatment for cardiogenicshock that rapidly and significantly improves blood pressure and cardiac output performa

  21. Slide 21: Istaroxime: Acute Heart Failure

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart

  22. Slide 22: Heart Failure — Large, Growing Market But Underserved

    Heart Failure —- Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing #1 cause of U.S. Annual Admissions Patients ~ hospitalization ~1.3M us 7Mus,, Wy in patients ~1. + > 65 years old 1.5M cv. 25M F worawide ~7% ByErsisB Gf o &) In-patient mortal

  23. Slide 23: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need Patient Management Goals Current Treatment Option: » Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: ~ Relieve pulmonary ~ Heart rhythm disturb

  24. Slide 24: Istaroxime AHF Phase 2a & 2b Studies

    Istaroxime AHF Phase 2a & 2b Studies 3) + Primary: PCWP significantly improved Phase + Stroke Vol & SBP — significantincrease 2a n=120 Dosing Ghour —._ Heart Rate (HR) - lowered ADHE Patients 0.5, 1, 1.5 yokomn Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 9.5, 1.0 ugkaimin Infusion (@yspnea

  25. Slide 25: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume Istaroxime 0.5 yig/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo gx Ele’ 23 Bas “0 Infusion period * pvalue = 0.029 pl infusion period “p-values 0.034 Cassie —hans tout ar Se) Seay ee 9 Plaeos-conett — esitzoine

  26. Slide 26: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 yig/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo 3? 1 pyalue=0.011 > Rt * paues £0005 Pressure (sBP) ae 4 i: | B ‘ inusionperoa Trusion period “mens en -0= Placedo-Conot2 — <=@eistaronim

  27. Slide 27: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins se fd WINDTREE ane ata pm) Istaroxime 0.5 ygikg/min vs. placebo Infusion period Cardiac Tat (Myocardial Damage) Istaroxime 1.0 g/kg/min vs. placebo *pwaue=0.011 ~"pvalues £0 068

  28. Slide 28: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias a L. L ta ‘Basen 1 Usa) Ow? Basen Day onsen) a2 sPacrbo-Conot—— mitaoxine Sugg sPctbo-Coon? istzuine 10K . Ventricular Tachycardia cams 700% — av 1 | an _ 00% 00% Basaine Oa Vso) a? oO ie Om ndson Da? & aPuc

  29. Slide 29: Istaroxime — Acute Heart Failure Phase 3 Program

    NIE Istaroxime — Acute Heart Failure Objective: Evaluate potential Phase 3 AHF program based on data from our cardiogenic shock program Potential Phase 3 AHF Program Augment our data from the positive phase 2a and phase 2b AHF studies = with the efficacy, safety and dosing and characterization learn

  30. Slide 30: Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2Za Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds + Oral & i.v. therapies for chronic “Next generation istaroxime” as

  31. Slide 31: Summary

    Summary vi" Istaroxime has produced positive, differentiating data in three Phase 2 studies for two separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient The data is consist

  32. Slide 32: Rostafuroxin: Resistant Hypertension

    Specifically displaces ouabain binding from the high affinity Na+— K+ATPase isoform present in the caveolae, antagonizing all the functional effects of ouabain SZ winotRee oy esistant Hypertension (RHTN Rostafuroxin There have been seven clinical studies of rostafuroxin in treatment naive hypertensi

  33. Slide 33: High Potential Value in Treatment Resistant Hypertension Market

    High Potential Value in Treatment Resistant Hypertension Market Large Market with Significant Unmet Need Significant Value Potential i i * Two biotech companies have * Treatment resistant hypertension ai An estimated 10% to 20% of demonstrated the significant value the i F market is placing on RHTN

  34. Slide 34: Active Engagement in Out-License and Partnership Opportunities

    Active Engagement in Out-License and Partnership Opportunities v AEROSURF / KL4 Platform — Exclusive global license to Lee’s Pharm (SEHK:950) and Zhaoke. Potential proceeds: ‘© Up to $78.9 million in potential milestone payments Gopal Bedional © Low double-digit % royalties Licensi © WINT no longer

  35. Slide 35: Financial Summary & Capitalization

    Financial Summary & Capitalization Investme Capital Efficiency to Prog Common Equivalents Securities | 35 of February 28, 2023 Significantly reduced company expenses and cash burn via out- licensing KL4 platform, focused resources on lead priority program Common Stock 904,459 = Total Company Burn /

  36. Slide 36: Strategy for Value Generation

    Strategy for Value Generation Communicate Our Milestones Transactions WA Optimization vv Secure focused BD Bring in new, well- transactions for deal revenue sulted development and non-dilutive financial supportof clinical opportunities and development transactions Progress heart failure platformto a

  37. Slide 37: Slide 37

Windtree Therapeutics — Investor Presentation (April 2023) on 6ix